Loading clinical trials...
Loading clinical trials...
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease
Conditions
Interventions
Aducanumab
Placebo
Locations
265
United States
Gilbert Neurology Partners, PLLC
Gilbert, Arizona, United States
Xenoscience Inc.
Phoenix, Arizona, United States
Banner Alzheimer's Institute
Phoenix, Arizona, United States
Barrow Neurological Institute
Phoenix, Arizona, United States
HonorHealth Neurology
Scottsdale, Arizona, United States
Mayo Clinic Arizona
Scottsdale, Arizona, United States
Start Date
June 2, 2022
Primary Completion Date
August 12, 2024
Completion Date
August 12, 2024
Last Updated
April 23, 2025
NCT07033494
NCT06159673
NCT07457138
NCT07422857
NCT07214727
NCT06584357
Lead Sponsor
Biogen
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions